CoChat
Sign Up
Cited by 9

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The Changing Microbial Environment and Chronic Inflammatory Disorders

Rook, Graham A.W.·2008·Allergy, Asthma & Clinical Immunology
DOI 10.1186/1710-1492-4-3-117PMC PMC2868866
Open this paper in CoChat — free account

Abstract

There is much to be gained from examining human diseases within the expanding framework of Darwinian medicine. This is particularly true of those conditions that change in frequency as populations develop from the human "environment of evolutionary adaptedness" to the living conditions of the rich industrialized countries. This development entails major changes in lifestyle, leading to reductions in contact with environmental microorganisms and helminths that have evolved a physiologic role as drivers of immunoregulatory circuits. It is suggested that a deficit in immunoregulation in rich countries is contributing not only to increases in the incidence of allergic disorders but also to increases in other chronic inflammatory conditions that are exacerbated by a failure to terminate inappropriate inflammatory reponses. These include autoimmunity, neuroinflammatory disorders, atherosclerosis, depression associated with raised inflammatory cytokines, and some cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1710-1492-4-3-117

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 70

  1. Strachan DP: Hay fever, hygiene, and household size. Br Med J. 1989, 299: 1259-60. 10.1136/bmj.299.6710.1259. · DOI · Paper page
  2. Strachan DP, Taylor EM, Carpenter RG: Family structure, neonatal infection, and hay fever in adolescence. Arch Dis Child. 1996, 74: 422-6. 10.1136/adc.74.5.422. · DOI
  3. Benn CS, Melbye M, Wohlfahrt J: Cohort study of sibling effect, infectious diseases, and risk of atopic dermatitis during first 18 months of life. BMJ. 2004, 328: 1223-10.1136/bmj.38069.512245.FE. · DOI
  4. Dunder T, Tapiainen T, Pokka T, Uhari M: Infections in child day care centers and later development of asthma, allergic rhinitis, and atopic dermatitis: prospective follow-up survey 12 years after controlled randomized hygiene intervention. Arch Pediatr Adolesc Med. 2007, 161: 972-7. 10.1001/archpedi.161.10.972. · DOI
  5. Umetsu DT, McIntire JJ, DeKruyff RH: TIM-1, hepatitis A virus and the hygiene theory of atopy: association of TIM-1 with atopy. J Pediatr Gastroenterol Nutr. 2005, 40 (Suppl 1): S43- · DOI
  6. Stanwell-Smith R, Bloomfield S: The hygiene hypothesis and its implications for home hygiene. 2004, Milan: NextHealth Srl
  7. Krug N, Madden J, Redington AE: T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol. 1996, 14: 319-26. · DOI
  8. Klunker S, Trautmann A, Akdis M: A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alphachemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J Immunol. 2003, 171: 1078-84. · DOI
  9. Lammas DA, Casanova JL, Kumararatne DS: Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin Exp Immunol. 2000, 121: 417-25. 10.1046/j.1365-2249.2000.01284.x. · DOI
  10. Rook GAW, Stanford JL: Give us this day our daily germs. Immunol Today. 1998, 19: 113-6. 10.1016/S0167-5699(97)01204-8. · DOI
  11. Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002, 347: 911-20. 10.1056/NEJMra020100. · DOI
  12. Stene LC, Nafstad P: Relation between occurrence of type 1 diabetes and asthma. Lancet. 2001, 357: 607-10.1016/S0140-6736(00)04067-8. · DOI
  13. Yazdanbakhsh M, Kremsner PG, van Ree R: Allergy, parasites, and the hygiene hypothesis. Science. 2002, 296: 490-4. 10.1126/science.296.5567.490. · DOI
  14. Akdis M, Verhagen J, Taylor A: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004, 199: 1567-75. 10.1084/jem.20032058. · DOI
  15. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004, 199: 971-9. 10.1084/jem.20031579. · DOI
  16. Kriegel MA, Lohmann T, Gabler C: Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med. 2004, 199: 1285-91. 10.1084/jem.20032158. · DOI
  17. Kraus TA, Toy L, Chan L: Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology. 2004, 126: 1771-8. 10.1053/j.gastro.2004.03.076. · DOI
  18. Powrie F, Read S, Mottet C: Control of immune pathology by regulatory T cells. Novartis Found Symp. 2003, 252: 92-8. full_text. · DOI
  19. Correale J, Farez M: Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol. 2007, 61: 97-108. 10.1002/ana.21067. · DOI
  20. Wildin RS, Smyk-Pearson S, Filipovich AH: Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 2002, 39: 537-45. 10.1136/jmg.39.8.537. · DOI
  21. Foley R: The adaptive legacy of human evolution: a search for the environment of evolutionary adaptedness. Evol Anthropol. 1995, 4: 194-203. 10.1002/evan.1360040603. · DOI
  22. Rook GA, Adams V, Hunt J: Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol. 2004, 25: 237-55. 10.1007/s00281-003-0148-9. · DOI
  23. Babu S, Blauvelt CP, Kumaraswami V, Nutman TB: Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence. J Immunol. 2006, 176: 3248-56. · DOI
  24. Kleij van der D, Latz E, Brouwers JF: A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates Toll-like receptor 2 and affects immune polarization. J Biol Chem. 2002, 277: 48122-9. 10.1074/jbc.M206941200. · DOI · Paper page
  25. Smits HH, Engering A, Kleij van der D: Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005, 115: 1260-7. 10.1016/j.jaci.2005.03.036. · DOI
  26. Pasare C, Medzhitov R: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003, 299: 1033-6. 10.1126/science.1078231. · DOI
  27. Zuany-Amorim C, Sawicka E, Manlius C: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med. 2002, 8: 625-9. 10.1038/nm0602-625. · DOI
  28. Wilson MS, Taylor MD, Balic A: Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J Exp Med. 2005, 202: 1199-212. 10.1084/jem.20042572. · DOI
  29. Ricklin-Gutzwiller ME, Reist M, Peel JE: Intradermal injection of heat-killed Mycobacterium vaccae in dogs with atopic dermatitis: a multicentre pilot study. Vet Dermatol. 2007, 18: 87-93. 10.1111/j.1365-3164.2007.00579.x. · DOI
  30. Zaccone P, Fehervari Z, Jones FM: Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur J Immunol. 2003, 33: 1439-49. 10.1002/eji.200323910. · DOI
  31. Summers RW, Elliott DE, Urban JF: Trichuris suis therapy in Crohn's disease. Gut. 2005, 54: 87-90. 10.1136/gut.2004.041749. · DOI · Paper page
  32. Rundek T, White H, Boden-Albala B: The metabolic syndrome and subclinical carotid atherosclerosis: the Northern Manhattan Study. J Cardiometab Syndr. 2007, 2: 24-9. 10.1111/j.1559-4564.2007.06358.x. · DOI
  33. Esposito K, Pontillo A, Giugliano F: Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab. 2003, 88: 1055-8. 10.1210/jc.2002-021437. · DOI
  34. Mallat Z, Ait-Oufella H, Tedgui A: Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med. 2007, 17: 113-8. 10.1016/j.tcm.2007.03.001. · DOI
  35. Mallat Z, Besnard S, Duriez M: Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999, 85: e17-24. · DOI
  36. Pinderski LJ, Fischbein MP, Subbanagounder G: Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002, 90: 1064-71. 10.1161/01.RES.0000018941.10726.FA. · DOI
  37. Ait-Oufella H, Salomon BL, Potteaux S: Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006, 12: 178-80. 10.1038/nm1343. · DOI
  38. Doenhoff MJ, Stanley RG, Griffiths K, Jackson CL: An antiatherogenic effect of Schistosoma mansoni infections in mice associated with a parasite-induced lowering of blood total cholesterol. Parasitology. 2002, 125: 415-21. 10.1017/S0031182002002275. · DOI
  39. Kuiper J, van Puijvelde GH, van Wanrooij EJ: Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol. 2007, 18: 521-6. 10.1097/MOL.0b013e3282efd0d4. · DOI
  40. Uyemura K, Demer LL, Castle SC: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996, 97: 2130-8. 10.1172/JCI118650. · DOI
  41. Mallat Z, Heymes C, Ohan J: Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol. 1999, 19: 611-6. · DOI
  42. Pinderski Oslund LJ, Hedrick CC, Olvera T: Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999, 19: 2847-53. · DOI
  43. Smith DA, Irving SD, Sheldon J: Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001, 104: 746-9. 10.1161/hc3201.094973. · DOI
  44. de Boer OJ, Meer van der JJ, Teeling P: Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE. 2007, 2: e779-10.1371/journal.pone.0000779. · DOI
  45. Rogers J, Mastroeni D, Leonard B: Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?. Int Rev Neurobiol. 2007, 82: 235-46. full_text. · DOI · Paper page
  46. Schmidt R, Schmidt H, Curb JD: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002, 52: 168-74. 10.1002/ana.10265. · DOI · Paper page
  47. Arosio B, Trabattoni D, Galimberti L: Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging. 2004, 25: 1009-15. 10.1016/j.neurobiolaging.2003.10.009. · DOI
  48. Ramos EM, Lin MT, Larson EB: Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset alzheimer disease. Arch Neurol. 2006, 63: 1165-9. 10.1001/archneur.63.8.1165. · DOI
  49. Etminan M, Gill S, Samii A: Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003, 327: 128-10.1136/bmj.327.7407.128. · DOI · Paper page
  50. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med. 2006, 12: 1005-15.
  51. Lio D, Licastro F, Scola L: Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun. 2003, 4: 234-8. 10.1038/sj.gene.6363964. · DOI
  52. Bagnoli S, Cellini E, Tedde A: Association of IL10 promoter polymorphism in Italian Alzheimer's disease. Neurosci Lett. 2007, 418: 262-5. 10.1016/j.neulet.2007.03.030. · DOI
  53. Ma SL, Tang NL, Lam LC, Chiu HF: The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol Aging. 2005, 26: 1005-10. 10.1016/j.neurobiolaging.2004.08.010. · DOI
  54. Depboylu C, Du Y, Muller U: Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease. Neurosci Lett. 2003, 342: 132-4. 10.1016/S0304-3940(03)00231-3. · DOI
  55. Bialecka M, Klodowska-Duda G, Kurzawski M: Interleukin-10 gene polymorphism in Parkinson's disease patients. Arch Med Res. 2007, 38: 858-63. 10.1016/j.arcmed.2007.06.006. · DOI
  56. Hakansson A, Westberg L, Nilsson S: Investigation of genes coding for inflammatory components in Parkinson's disease. Mov Disord. 2005, 20: 569-73. 10.1002/mds.20378. · DOI
  57. Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27: 24-31. 10.1016/j.it.2005.11.006. · DOI · Paper page
  58. Wilson AG, Gordon C, di Giovine FS: A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol. 1994, 24: 191-5. 10.1002/eji.1830240130. · DOI
  59. Lichtenstein GR, Bala M, Han C: Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis. 2002, 8: 237-43. 10.1097/00054725-200207000-00001. · DOI
  60. Parissis JT, Adamopoulos S, Rigas A: Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol. 2004, 94: 1326-8. 10.1016/j.amjcard.2004.07.127. · DOI
  61. Kubera M, Lin AH, Kenis G: Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001, 21: 199-206. 10.1097/00004714-200104000-00012. · DOI · Paper page
  62. Lowry CA, Hollis JH, de Vries A: Identification of an immune-responsive mesolimbocortical serotonergic system: potential role in regulation of emotional behavior. Neuroscience. 2007, 146: 756-72. 10.1016/j.neuroscience.2007.01.067. · DOI · Paper page
  63. Rook GAW, Lowry CA: The hygiene hypothesis and psychiatric disorders. Trends Immunol. 2008, 29: 150-8. 10.1016/j.it.2008.01.002. · DOI
  64. Aggarwal BB, Shishodia S, Sandur SK: Inflammation and cancer: how hot is the link?. Biochem Pharmacol. 2006, 72: 1605-21. 10.1016/j.bcp.2006.06.029. · DOI · Paper page
  65. Pikarsky E, Porat RM, Stein I: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431: 461-6. 10.1038/nature02924. · DOI
  66. Arnott CH, Scott KA, Moore RJ: Expression of both TNFalpha receptor subtypes is essential for optimal skin tumour development. Oncogene. 2004, 23: 1902-10. 10.1038/sj.onc.1207317. · DOI
  67. Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007, 369: 1603-13. 10.1016/S0140-6736(07)60747-8. · DOI · Paper page
  68. Murphy SJ, Anderson LA, Johnston BT: Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study. World J Gastroenterol. 2005, 11: 7290-5. · DOI
  69. Wang HY, Wang RF: Regulatory T cells and cancer. Curr Opin Immunol. 2007, 19: 217-23. 10.1016/j.coi.2007.02.004. · DOI
  70. Deans C, Rose-Zerilli M, Wigmore S: Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol. 2007, 14: 329-39. 10.1245/s10434-006-9122-9. · DOI

Cited by

Sorted by citations

See all 9

Metadata

Authors
Rook, G. A. W.
Venue
Allergy, Asthma & Clinical Immunology
Publisher
Springer Science and Business Media LLC
Published
2008-09
Volume
4
Issue
3
ISSN
1710-1492
DOI
10.1186/1710-1492-4-3-117
PMC
PMC2868866
Cited by
9
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Changing Microbial Environment and Chronic Inflammatory Disorders. https://app.cochat.ai/papers/10.1186/1710-1492-4-3-117
The paper
Rook, G. A. W. (2008). The Changing Microbial Environment and Chronic Inflammatory Disorders. Allergy, Asthma & Clinical Immunology. https://doi.org/10.1186/1710-1492-4-3-117